

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number
WO 2005/045035 A2

(51) International Patent Classification⁷: C12N 15/11

(21) International Application Number:
PCT/US2004/026930

(22) International Filing Date: 20 August 2004 (20.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

10/693,059	23 October 2003 (23.10.2003)	US
10/720,448	24 November 2003 (24.11.2003)	US
10/727,780	3 December 2003 (03.12.2003)	US
10/757,803	14 January 2004 (14.01.2004)	US
60/543,480	10 February 2004 (10.02.2004)	US
10/780,447	13 February 2004 (13.02.2004)	US
10/826,966	16 April 2004 (16.04.2004)	US
PCT/US04/13456	30 April 2004 (30.04.2004)	US
PCT/US04/16390	24 May 2004 (24.05.2004)	US

(71) Applicant (for all designated States except US): SIRNA
THERAPEUTICS, INC. [US/US]; 2950 Wilderness
Place, Boulder, CO 80301 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MCSWIGGEN,
James [US/US]; 4866 Franklin Drive, Boulder, CO 80301
(US). CHOWRIRA, Bharat, M. [US/US]; 576 Manor-
wood Lane, Louisville, CO 80027 (US). HAEBERLI,
Peter [US/US]; 705 7th Street, Boulder, CO 80513 (US).

(74) Agent: TERPSTRA, Anita, J.; McDonnell Bochen Hül-
bert & Berghoff LLP, 300 South Wacker Drive, Suite 3200,
Chicago, IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION US-
ING SHORT INTERFERING NUCLEIC ACID (siNA)

(57) Abstract: This invention relates to compounds, compositions, and methods useful for modulating NOGO and/or NOGO recep-
tor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions,
and methods useful for modulating the expression and activity of other genes involved in pathways of NOGO and/or NOGO re-
ceptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant
invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), dou-
ble-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the
expression of NOGO and/or NOGO receptor genes, such as NOGO-A, NOGO-B, NOGO-C, NOGO-66 receptor, NI-35, NI-220,
NI-250, myelin-associated glycoprotein, tenascin-R, and NG-2



WO 2005/045035 A2

Best Available Copy